SARATOGA, Calif.--(BUSINESS WIRE)--The Myelin Repair Foundation (MRF), a research nonprofit organization dedicated to the discovery and development of myelin repair therapeutics for multiple sclerosis (MS), today announced the appointment of Dr. Ted Yednock, Ph.D. to its Drug Discovery Advisory Board. Most recently the Executive Vice President, Head of Research at Elan Pharmaceuticals and inventor of the Tysabri antibody, Dr. Yednock joins the Drug Discovery Advisory Board at the MRF to bring top industry expertise in developing therapeutics for MS patients.
“I have built my career around trying to better the lives of patients with autoimmune and neurodegenerative conditions, with a particular emphasis on uncovering innovative MS treatments. The Myelin Repair Foundation shares my drive for accelerating research discoveries to patients,” said Dr. Yednock. “I am thrilled to begin working more closely with the MRF as a member of its drug discovery board, being part of a team focused on uncovering the next generation of MS therapeutics for patients that will repair the brain.”
Dr. Yednock is best known in the MS community for developing Tysabri, a drug designed to slow worsening disability and reduce flare-ups in adults with MS that received FDA approval in 2004. Prior to his most recent role as Executive Vice President, Head of Research at Elan Pharmaceuticals, Dr. Yednock worked for Athena Neurosciences in a series of scientific and leadership positions, where he spearheaded MS, Parkinson’s and Alzheimer’s research initiatives. Dr. Yednock joins the industry experts on the MRF’s Drug Discovery Advisory Board, which consists of members from the pharmaceutical industry with in-depth knowledge in drug discovery and clinical development of new therapeutics.
“Dr. Yednock is highly regarded as a leader who achieved something very few have accomplished—invented a new therapeutic for patients,” said Scott Johnson, CEO, president and founder of the Myelin Repair Foundation. “His vast expertise in drug discovery and development, along with his past successes will be a valuable asset to the MRF Drug Discovery Advisory Board. I am pleased to welcome Dr. Yednock to join our quest to accelerate the discovery and development of myelin repair therapeutics.”
About the Myelin Repair Foundation
The Myelin Repair Foundation (MRF) (http://www.myelinrepair.org) is a Silicon Valley-based, non-profit research organization focused on accelerating the discovery and development of myelin repair therapeutics for multiple sclerosis. Its Accelerated Research Collaboration™ (ARC™) model is designed to optimize the entire process of medical research, drug development and the delivery of patient treatments.
